Clinical Trial Update: An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

This update notes the termination of an open-label safety and tolerability continuation study of intracerebroventricular sNN0029 in patients with amyotrophic la…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• sNN0029

Snippet

Sponsor: Newron Sweden AB | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: TERMINATED